Distinguished in Peripheral T-Cell Lymphoma

Norbert D. Schmitz

AsklepiosKlinik St Georg, 
Hamburg, HH, DE 
Distinguished in Peripheral T-Cell Lymphoma
AsklepiosKlinik St Georg, 
Hamburg, HH, DE 
OverviewLocationsClinical Research

Overview

Norbert Schmitz practices in Hamburg, Germany. Mr. Schmitz is rated as a Distinguished expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 407 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles and participated in 1 clinical trial in the study of Peripheral T-Cell Lymphoma.

Gender
Male

Locations

AsklepiosKlinik St Georg, Hamburg, HH, Germany
Other Locations
Hoppe Seyler Str. 9, Tuebingen, BW 72076, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drugs: Peginterferon ?2b, Nilotinib
Study Phase: Phase 3
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: Romidepsin, CHOP
Study Phase: Phase 3
Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis: A Randomized Controlled Trial
Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis: A Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: October 25, 2022
Intervention Type: Behavioral
Study Phase: Not Applicable
Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)
Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)
Enrollment Status: Terminated
Publish Date: October 29, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 3
The Impact of Disclosing Personalized Depression Risk Information on High-risk Individuals' Outcomes
The Impact of Disclosing Personalized Depression Risk Information on High-risk Individuals' Outcomes
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Other
Study Phase: Not Applicable
The Effects of E-mental Health Program and Job Coaching on the Risk of Major Depression and Productivity in Canadian Male Workers
The Effects of E-mental Health Program and Job Coaching on the Risk of Major Depression and Productivity in Canadian Male Workers
Enrollment Status: Completed
Publish Date: May 17, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 6 Less Clinical Trials

407 Total Publications

Prospective associations between diabetes and depressive symptoms across European regions: a secondary analysis of ELSA, TILDA, and SHARE datasets.
Prospective associations between diabetes and depressive symptoms across European regions: a secondary analysis of ELSA, TILDA, and SHARE datasets.
Journal: European journal of public health
Published: September 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schmitz's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile